Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;7(23):775.
doi: 10.21037/atm.2019.11.37.

Prognostic value of skeletal muscle index and monocyte-to-lymphocyte ratio for lymph node-positive breast cancer patients after mastectomy

Jia-Peng Deng  1   2 , Xin Hua  1   2 , Zhi-Qing Long  1   2 , Wen-Wen Zhang  1   2 , Huan-Xin Lin  1   2 , Zhen-Yu He  1   2
Affiliations

Prognostic value of skeletal muscle index and monocyte-to-lymphocyte ratio for lymph node-positive breast cancer patients after mastectomy

Jia-Peng Deng et al. Ann Transl Med. 2019 Dec.

Erratum in

Abstract

Background: We aimed to assess the prognostic value of the skeletal muscle index (SMI) and monocyte-to-lymphocyte ratio (MLR) in lymph node-positive breast cancer patients after mastectomy.

Methods: We enrolled female lymph node-positive breast cancer patients who had undergone mastectomy between January 2011 and December 2013 with lymph node metastasis. Skeletal muscle tissue was measured using computed tomography (CT), and the patients were grouped based on the receiver operating characteristic curves to obtain the cut-off point for SMI; similarly, the optimal cutoff point for the MLR was obtained. Survival analysis was chiefly performed to determine overall survival (OS) among the patients.

Results: The median age of the 97 included patients was 46 years (range, 27-73 years), whereas the median follow-up duration was 62.5 months. Of these patients, 71 exhibited low SMI and 66 exhibited high MLR. Kaplan-Meier curves indicated that low SMI (5-year OS, 97.2% vs. 84.6%; log-rank P=0.021) and low MLR (5-year OS, 98.5% vs. 83.9%; log-rank P=0.004) were associated with better OS. Moreover, patients with both high SMI and MLR (high SMLR) had significantly worse OS (5-year OS, 66.7% vs. 96.6%; log-rank P<0.001), relative to the low SMLR group. Multivariate analysis indicated that patients with low SMI had a lower overall dying risk, relative to those with high SMI [hazard ration (HR), 0.188; P=0.038], whereas patients with high MLR had a higher risk of death as compared to those with low MLR (HR, 7.152; P=0.021). Furthermore, SMLR was an independent prognostic factor of poor OS (HR, 13.272; P=0.001).

Conclusions: Low SMI and low MLR are both associated with better OS in lymph node-positive breast cancer patients after mastectomy. SMI combined with MLR (SMLR) may be powerful prognosis factor for OS among these patients.

Keywords: Skeletal muscle index (SMI); breast cancer; monocyte-to-lymphocyte ratio (MLR); survival.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Computed tomography (CT) image of the third lumbar vertebra with highlighted body composition: skeletal muscle mass (SMM) in pink, visceral adipose tissue (VAT) in yellow, and subcutaneous adipose tissue (SAT) in blue.
Figure 2
Figure 2
Kaplan-Meier curves showing the overall survival (OS) rates of groups based on SMI (A), MLR (B), and SMLR (C). SMI, skeletal muscle index; MLR, monocyte-to-lymphocyte ratio.
Figure S1
Figure S1
Kaplan-Meier curves showing the RFS and DFS rates of groups based on SMI (A,B) and MLR (C,D). RFS, recurrence-free survival; DFS, disease-free survival; SMI, skeletal muscle index; MLR, monocyte-to-lymphocyte ratio.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol 2018;4:798-804. 10.1001/jamaoncol.2018.0137 - DOI - PMC - PubMed
    1. Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr 1993;123:465-8. 10.1093/jn/123.suppl_2.465 - DOI - PubMed
    1. Cooper C, Fielding R, Visser M, et al. Tools in the assessment of sarcopenia. Calcif Tissue Int 2013;93:201-10. 10.1007/s00223-013-9757-z - DOI - PMC - PubMed
    1. Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med 2011;365:565-7. 10.1056/NEJMcibr1106880 - DOI - PubMed
    1. Murata M. Inflammation and cancer. Environ Health Prev Med 2018;23:50. 10.1186/s12199-018-0740-1 - DOI - PMC - PubMed